X

Trial Profile

Multicenter Pilot Phase III Clinical Trial of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetirizine (Primary) ; Diphenhydramine
Indications Hypersensitivity; Urticaria
Focus Registrational; Therapeutic Use
Acronyms ETTAU-02
Sponsors JDP Therapeutics

Most Recent Events

08 Jan 2015 Top-line results published in JDP Therapeutics media release.
08 Jan 2015 Primary endpoint (Reduction in Acute Urticaria symptom score) has been met, according to a JDP Therapeutics media release.
08 Jan 2015 Status changed from recruiting to completed, according to a JDP Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com